CN1720917A - Cough treating orally disintegrating tablet - Google Patents
Cough treating orally disintegrating tablet Download PDFInfo
- Publication number
- CN1720917A CN1720917A CN 200410060404 CN200410060404A CN1720917A CN 1720917 A CN1720917 A CN 1720917A CN 200410060404 CN200410060404 CN 200410060404 CN 200410060404 A CN200410060404 A CN 200410060404A CN 1720917 A CN1720917 A CN 1720917A
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- dextromethorphan hydrobromide
- tablet
- disintegration tablet
- cavity disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses an oral disintegrating tablet for treating cough, whose medicinal active component is dextromethorphan hydrobromide, the weight portions for each component are, dextromethorphan Hydrobromide 1 part, filling agent 1-30 parts, crumbling agent 0.4-5 parts, flavoring agent 0.01-0.08 part. The tablet has the advantages of right hardness, good taste, quick action, facilitated administration and carrying. Its disintegration time is superior to the common tablets, its stability is higher than the solution agent. The tablet is recommended for children, the aged people, patients with deglutition obstacle or in field operations.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, particularly a kind of dextromethorphan hydrobromide oral cavity disintegration tablet for the treatment of cough.
Background technology
The dextromethorphan hydrobromide dosage form of existing treatment cough is that conventional tablet and child use oral liquid formulations, the conventional tablet dissolution time generally was limited to 30 minutes, and stripping quantity is 80% of a sign amount, and onset is slower, to under swallowed the obstacle person and the inconvenient situation of fetching water, take very inconvenience.Oral liquid formulations is not easy to carry, less stable.
Summary of the invention
The object of the invention is to provide a kind of dextromethorphan hydrobromide oral cavity disintegration tablet of treatment cough of taking convenience.
For reaching above-mentioned purpose, the present invention adopts following technical scheme: a kind of oral cavity disintegration tablet for the treatment of cough, active constituents of medicine are dextromethorphan hydrobromide.
The parts by weight of each component are 1 part of dextromethorphan hydrobromide, filler 1-30 part, disintegrating agent 0.4-5 part, correctives 0.01-0.08 part.
Disintegrating agent is selected microcrystalline Cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose sodium, cross-linking sodium carboxymethyl cellulose or its mixture for use.
Filler is selected pre-paying starch, microcrystalline Cellulose, mannitol, lactose or its mixture for use
Correctives selects that A Siba is sweet for use, steviol glycosides, Herba Menthae essence or its mixture.
Among the present invention, the English Dextromethorphan Hydrobromide by name of dextromethorphan hydrobromide, chemical name is dextrorotation-3-methoxyl group morphinan hydrobromate-hydrate, molecular formula C
18H
25NOHBrH
2O.
The present invention makes oral cavity disintegration tablet with cough-relieving effective ingredient dextromethorphan hydrobromide, need not water when taking, medicine is placed directly on the lingual surface, meet the rapid disintegrate of saliva, borrow swallowing act to go into stomach, rapid-action, cough-relieving rapidly, be easy to carry and take, overcome the deficiency of the oral liquid existence of conventional tablet and children taking, can improve child, old man or swallow the compliance of patient's medication of obstacle person and field work, make fast Absorption behind the drug administration and reach the therapeutical effect of quick cough-relieving.
The present invention can adopt conventional tablet pharmaceutical equipment to produce and use the pressing process preparation, adds in disintegrating agent adopts and adds two kinds of methods.Concrete method for making is as described below: main ingredient is crossed 120 orders with upper screen cloth, take by weighing respectively by recipe quantity, active constituents of medicine is mixed with filler, part disintegrating agent and correctives, 60% alcohol granulation, drying adds part disintegrating agent, essence and lubricant, mix homogeneously, tabletting are promptly.Technology is simple, is convenient to grasp, and has promotional value.
Moderate, the good mouthfeel of oral cavity disintegration tablet hardness of the present invention need not water when taking, also need not to chew, medicine is placed directly on the lingual surface, meet saliva disintegrate in 30 seconds, borrow swallowing act to go into that stomach absorbs and the effect that reaches rapid cough-relieving, and be easy to carry and take.Utilize oral cavity test, simulation oral cavity experimental test this product disintegration time, can reach of the requirement of present China oral cavity disintegration tablet.The method of the test of oral cavity disintegration tablet oral cavity, simulation oral cavity experimental test this product disintegration time is as follows:
Oral cavity test: select 6 healthy volunteers, get 6 of this product, respectively put a slice in the oral cavity, allow its disintegrate voluntarily, write down complete disintegrate, as disintegration time, should spend 30 seconds, and mouthfeel is suitable, and grittiness must not be arranged to the time of not having block.
The test of simulation oral cavity: get a plate, add water 2ml, with a filter paper doubling, put into plate, get 6 of this product, put on the filter paper, record absorbs water the time of moistening and disintegrate fully, and spreads out with glass rod immediately, and fully whether observing, disintegrate is a fine grained.It's 30 seconds should past time.
The specific embodiment
The oral cavity disintegration tablet of embodiment 1, treatment cough, make by following component:
Dextromethorphan hydrobromide 7.5g
Microcrystalline Cellulose 32.0g
Mannitol 28.0g
Lactose 20.0g
Pre-paying starch 6.0g
Crospolyvinylpyrrolidone 18.0g
The sweet 0.5g of A Siba
Herba Menthae essence 0.1ml
Micropowder silica gel 1.0g,
Make 1000 altogether.
Concrete preparation method is as follows: dextromethorphan hydrobromide, microcrystalline Cellulose, mannitol, lactose, pre-paying starch, crospolyvinylpyrrolidone, A Siba is sweet, micropowder silica gel pulverize separately is crossed 120 mesh sieves, takes by weighing by formula ratio.Earlier that dextromethorphan hydrobromide and A Siba is sweet, mannitol, lactose, pre-paying starch mix homogeneously, again with 2/3 amount microcrystalline Cellulose, the half crospolyvinylpyrrolidone mix homogeneously of measuring, 60% alcohol granulation, dry, granulate with second half crospolyvinylpyrrolidone, 1/3 amount microcrystalline Cellulose, the micropowder silica gel mixing that sieves, carries out the intermediate content detection, spray into Herba Menthae essence, tabletting promptly.The disintegrating tablet of producing is through oral cavity test, simulation oral cavity experimental test, and disintegration time is 26 seconds.
In embodiment 2, the present embodiment, the oral cavity disintegration tablet of treatment cough is made by following component:
Dextromethorphan hydrobromide 15.0g
Microcrystalline Cellulose 30.0g
Mannitol 30.0g
Lactose 22.0g
Pre-paying starch 6.0g
Crospolyvinylpyrrolidone 10.0g
Cross-linking sodium carboxymethyl cellulose 10.0g
Steviol glycosides 1.0g
Herba Menthae essence 0.2ml
Hard magnesium 0.8g,
Make 1000 altogether.
Concrete preparation method is as follows: with dextromethorphan hydrobromide, microcrystalline Cellulose, mannitol, lactose, pre-paying starch, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose, steviol glycosides, the hard magnesium pulverize separately is crossed 120 mesh sieves, connecing formula ratio takes by weighing, earlier with dextromethorphan hydrobromide and the abundant mix homogeneously of steviol glycosides, add mannitol again, lactose and pre-paying starch mix homogeneously, again with 1/3 amount microcrystalline Cellulose, the crospolyvinylpyrrolidone and the cross-linking sodium carboxymethyl cellulose mix homogeneously of half amount, 50% alcohol granulation, dry, granulate, with second half crospolyvinylpyrrolidone and cross-linking sodium carboxymethyl cellulose, 2/3 amount microcrystalline Cellulose, the hard magnesium mixing that sieves, spray into Herba Menthae essence, carry out the intermediate content detection, tabletting promptly.The disintegrating tablet of producing is through oral cavity test, simulation oral cavity experimental test, and disintegration time is 28 seconds.
In embodiment 3, the present embodiment, the oral cavity disintegration tablet of treatment cough is made by following component:
Dextromethorphan hydrobromide 30.0g
Microcrystalline Cellulose 28.0g
Mannitol 30.g
Lactose 18.0
Low-substituted hydroxypropyl cellulose sodium 12.0g
Cross-linking sodium carboxymethyl cellulose 10.0g
The sweet 0.8g of A Siba
Steviol glycosides 0.6g
Herba Menthae essence 0.2ml
Micropowder silica gel 0.4g
Hard magnesium 0.5g,
Make 1000 altogether.
Concrete preparation method is as described below: with dextromethorphan hydrobromide, microcrystalline Cellulose, mannitol, lactose, low-substituted hydroxypropyl cellulose sodium, cross-linking sodium carboxymethyl cellulose, steviol glycosides, A Siba is sweet, micropowder silica gel, the hard magnesium pulverize separately is crossed 120 mesh sieves, take by weighing by formula ratio, earlier with dextromethorphan hydrobromide, sweet and the abundant mix homogeneously of steviol glycosides of A Siba, add microcrystalline Cellulose again, mannitol, the lactose mix homogeneously, with low-substituted hydroxypropyl cellulose sodium, cross-linking sodium carboxymethyl cellulose half and half amount mix homogeneously, 50% alcohol granulation, dry, granulate, again with second half low-substituted hydroxypropyl cellulose sodium, cross-linking sodium carboxymethyl cellulose and micropowder silica gel, the hard magnesium mixing that sieves, spray into Herba Menthae essence, carry out the intermediate content detection, tabletting promptly.The disintegrating tablet of producing is through oral cavity test, simulation oral cavity experimental test, and disintegration time is 22 seconds.
In the foregoing description, micropowder silica gel and hard magnesium lubricate.
Claims (5)
1, a kind of oral cavity disintegration tablet for the treatment of cough is characterized in that, active constituents of medicine is a dextromethorphan hydrobromide.
2, oral cavity disintegration tablet according to claim 1 is characterized in that, the parts by weight of each component are 1 part of dextromethorphan hydrobromide, filler 1-30 part, disintegrating agent 0.4-5 part, correctives 0.01-0.08 part.
3, oral cavity disintegration tablet according to claim 2 is characterized in that, disintegrating agent is selected microcrystalline Cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose sodium, cross-linking sodium carboxymethyl cellulose or its mixture for use.
4, oral cavity disintegration tablet according to claim 2 is characterized in that, filler is selected pre-paying starch, microcrystalline Cellulose, mannitol, lactose or its mixture for use
5, oral cavity disintegration tablet according to claim 2 is characterized in that, correctives selects that A Siba is sweet for use, steviol glycosides, Herba Menthae essence or its mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060404 CN1720917A (en) | 2004-07-12 | 2004-07-12 | Cough treating orally disintegrating tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060404 CN1720917A (en) | 2004-07-12 | 2004-07-12 | Cough treating orally disintegrating tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1720917A true CN1720917A (en) | 2006-01-18 |
Family
ID=35911753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410060404 Pending CN1720917A (en) | 2004-07-12 | 2004-07-12 | Cough treating orally disintegrating tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1720917A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114469882A (en) * | 2022-04-06 | 2022-05-13 | 北京剂泰医药科技有限公司 | Dextromethorphan quinidine orally disintegrating tablet and application thereof |
-
2004
- 2004-07-12 CN CN 200410060404 patent/CN1720917A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114469882A (en) * | 2022-04-06 | 2022-05-13 | 北京剂泰医药科技有限公司 | Dextromethorphan quinidine orally disintegrating tablet and application thereof |
| WO2023193745A1 (en) * | 2022-04-06 | 2023-10-12 | 北京剂泰医药科技有限公司 | Dextromethorphan-quinidine orally disintegrating tablet and use thereof |
| CN114469882B (en) * | 2022-04-06 | 2023-10-20 | 北京剂泰医药科技有限公司 | Right American Sha Fenkui Neoprene orally disintegrating tablet and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1339972A (en) | Tablets quickly disintegrated in the oral cavity | |
| CN101198327B (en) | Solid compositions for treating middle-of-the-night insomnia and method therefor | |
| CN1742743A (en) | Pseudo-ginseng saponin oral disintegration tablet and preparing method | |
| CN100339081C (en) | Oral loratadine disintegrating tablet and its prepn | |
| CN1720917A (en) | Cough treating orally disintegrating tablet | |
| CN1247195C (en) | Silibinin oral disintegration tablet and its preparing method | |
| CN1631425A (en) | Lozenge for treating its pharyngitis and preparation process thereof | |
| CN1830442A (en) | Compound formula dextro methaphen oral disintegration tablet and its preparation method | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN100348180C (en) | Oral disintegration tablet of tramadol hydrochloride and preparation method | |
| CN1202825C (en) | Difenidol Hydrochloride oral disintegrating tablet and preparation process thereof | |
| CN1279896C (en) | Tramadol hydrochloride oral disintegration tablets, and prepn. method therefor | |
| CN1634428A (en) | Ginkgo leaf soft capsule and preparation technique thereof | |
| CN100394917C (en) | Bilobanoate oral-cavity disintegrating tablet and preparation method | |
| CN1850206A (en) | Medicine for treating women's climateric syndrome and preparing method | |
| CN1562013A (en) | Nisoldipine oral disintegration tablet for treating hypertension and preparing method | |
| CN1739514A (en) | Oral loratadine disintegrating tablet and its prepn | |
| CN1383814A (en) | Oral quick disintegrating tablet and its prepn process | |
| CN1270721C (en) | Rapid disintegration and rapid dissolution tablet containing kakonein | |
| CN1954806A (en) | Teprenone orally disintegrating tablet prescription and its preparation method | |
| CN1879641A (en) | Dispersible tablet of glycyrrhizin and preparation method thereof | |
| CN1923185A (en) | Gastrodine tablets disintegrating in oral cavity and process for producing same | |
| CN1927372A (en) | Antiviral dispersant tablet and method for making same | |
| CN1586597A (en) | Ginseng oral disintegration tablet and its preparing process | |
| CN1593398A (en) | Daidzein dispersible tablet composition and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |